GlassScriptPhysician profile
Naresh P Singh
NPI 1790721116
$111,458.51
in general payments reported to CMS, 2019-2025
20 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $13K · 2021: $11K · 2022: $13K · 2023: $18K · 2024: $9,173 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Food and Beverage: $4,070 · Education: $389 · Consulting Fee: $200 · Travel and Lodging: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,960.00 |
| Food and Beverage | $4,070.02 |
| Education | $389.28 |
| Consulting Fee | $200.00 |
| Travel and Lodging | $145.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $43,595.28 | 2020-2025 | Breztri, Airsupra |
| Mylan Specialty L.P. | $34,253.45 | 2019-2022 | |
| Grifols USA, LLC | $19,203.56 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,991.98 | 2019-2025 | Ofev, Jascayd |
| Actelion Pharmaceuticals US, INC. | $1,163.47 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Grifols Shared Services North America, INC. | $820.00 | 2023 | Prolastin-C Liquid |
| United Therapeutics Corporation | $545.96 | 2021-2025 | Tyvaso |
| Melinta Therapeutics, LLC | $453.85 | 2019-2024 | Rezzayo, Kimyrsa |
| Merck Sharp & Dohme LLC | $404.94 | 2022-2025 | Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $341.15 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $322.14 | 2019 | |
| Glaxosmithkline, LLC. | $114.88 | 2022-2025 | Trelegy Ellipta |
| Intuitive Surgical, INC. | $98.21 | 2023 | |
| Paratek Pharmaceuticals, INC. | $69.77 | 2020-2021 | |
| Verona Pharma, INC. | $51.95 | 2025 | Ohtuvayre |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $16.24 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.68 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naresh Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.